文献速递主动脉疾病

腹主动脉瘤患者心血管疾病预防药物强度性别差异分析——单中心横断面研究

Analyzing Sex Differences in Intensity of Cardiovascular Disease Prevention Medications in Patients With Abdominal Aortic Aneurysms-A Single-Center Cross-Sectional Study.
PubMed 文献 · Ann Vasc Surg · 2022-11-29

该单中心回顾性横断面研究纳入614例腹主动脉瘤监测项目患者,评估抗血栓治疗、降脂治疗强度及血脂监测的总体情况和性别差异。结果显示21%未用抗血栓治疗、20%未用降脂治疗、47%使用低/中强度他汀;女性降脂治疗处方可能性独立降低(P=0.008,ηp2=0.012,效应量小),LDL-C监测及达标率均较低(平均差9%,P=0.040)。

要点

  • 21%患者未接受抗血栓治疗,20%未接受降脂治疗,47%使用低/中强度他汀。
  • 女性降脂治疗处方可能性独立降低(P=0.008,ηp2=0.012,效应量小)。
  • 女性LDL-C监测及达标<1.4 mmol/L的比例均较低(平均差9%,P=0.040)。

核心结论

  • 两性在心血管风险预防的这些方面均有改善空间。
  • 腹主动脉瘤患者降脂治疗处方、血脂监测普及率及LDL-C达标可能性存在性别差异,女性普及率较低。

研究设计与样本

  • 回顾性、单中心、横断面研究,纳入614例某三级血管外科单位腹主动脉瘤监测项目患者。
  • 评估2018年1月1日至2020年12月31日期间至少接受1次监测扫描的所有患者。
  • 查询与实时初级保健记录链接的电子医院记录,获取人口学、合并症、抗血小板和降脂治疗处方及血清胆固醇实验室结果。
  • 使用协方差分析校正混杂合并症的影响。

主要发现

  • 21%患者未接受抗血栓治疗,20%患者未接受降脂治疗,反映该组患者临床照护欠佳。
  • 47%队列使用低/中强度他汀治疗,反映该组患者照护有改善空间。
  • 女性与降脂治疗处方可能性降低独立相关(P=0.008,ηp2=0.012,效应量小),但与抗血栓治疗无关(P=0.202)。
  • 较少女性接受LDL-C监测(平均差9%,P=0.040)并达到欧洲心脏病学会-欧洲动脉粥样硬化学会LDL-C目标<1.4 mmol/L(平均差9%,P=0.040)。

关键数值与推荐

  • 欧洲血管外科学会腹主动脉瘤指南建议所有腹主动脉瘤患者应考虑抗血小板治疗和降脂治疗。
  • 欧洲心脏病学会-欧洲动脉粥样硬化学会LDL-C目标为<1.4 mmol/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with abdominal aortic aneurysm (AAA) are at a significant risk of cardiovascular events, similar to that of patients who have already experienced a major cardiac event. The European Society for Vascular Society AAA guidelines suggest that antiplatelet therapy and lipid-lowering therapy (LLT) should be considered in all patients with AAA. This study explores the overall prevalence and intensity of antithrombotic therapy and LLT, and lipid profile monitoring in a single center AAA surveillance cohort alongside any sex differences. METHODS: This was a retrospective, single center, cross-sectional study of 614 patients enrolled in the AAA surveillance program of a tertiary vascular surgery unit. All patients undergoing at least 1 surveillance scan from January 1, 2018, to December 31, 2020, were assessed. Electronic hospital records linked to real-time primary care records were interrogated for data on demographics, comorbidities, antiplatelet and LLT prescriptions, and serum cholesterol laboratory results. An analysis of covariance test was used to account for the effects of confounding comorbidities. RESULTS: Twenty-one percent of patients were not on antithrombotic therapy, and 20% of patients were not on LLT which reflects a group of patients receiving sub-optimal clinical care. In total, 47% of the cohort were on low/moderate intensity statin therapy which reflects a group of patients where care can be improved upon. Female sex was independently associated with a reduced likelihood of being prescribed LLT (P = 0.008, eta squared (ηp2) = 0.012, small effect size) but not antithrombotic therapy (P = 0.202). Fewer women underwent low-density lipoprotein cholesterol (LDL-C) monitoring (mean difference 9%, P = 0.040) and achieved the European Society of Cardiology-European Atherosclerosis Society- LDL-C target of <1.4 mmol/L (mean difference 9%, P = 0.040). CONCLUSIONS: Overall, there is room for improvement in these aspects of cardiovascular risk prevention for both sexes. Sex differences in the prescription of LLT, the prevalence of lipid profile monitoring, and likelihood of achieving LDL-C targets exist among patients with AAA, with a lower prevalence in women.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kwan JY, Tang SH, Davies H, et al. Analyzing Sex Differences in Intensity of Cardiovascular Disease Prevention Medications in Patients With Abdominal Aortic Aneurysms-A Single-Center Cross-Sectional Study. Ann Vasc Surg. 2022. PMID: 36460174. doi:10.1016/j.avsg.2022.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。